| Hegira Health, Inc | |
|
8623 N Wayne Road Suite 310 Westland MI 48185 | |
| (734) 425-0636 | |
| (734) 425-4771 |
| Full Name | Hegira Health, Inc |
|---|---|
| Speciality | Clinic/Center |
| Location | 8623 N Wayne Road, Westland, Michigan |
| Authorized Official Name and Position | Carol L. Zuniga (CEO) |
| Authorized Official Contact | 7344991513 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Hegira Health, Inc 37450 Schoolcraft Suite 110 Livonia MI 48150-1000 Ph: (734) 458-4601 | Hegira Health, Inc 8623 N Wayne Road Suite 310 Westland MI 48185 Ph: (734) 425-0636 |
| NPI Number | 1184684979 |
|---|---|
| Provider Enumeration Date | 03/24/2006 |
| Last Update Date | 08/09/2022 |
| Certification Date | 08/09/2022 |
| Medicare PECOS PAC ID | 3173429560 |
|---|---|
| Medicare Enrollment ID | O20031208000753 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184684979 | NPI | - | NPPES |
| 1706651 | Medicaid | MI | |
| 3094619 | Medicaid | MI |
| Provider Name | Keum Duk Kang Chun |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1881627941 PECOS PAC ID: 6305750456 Enrollment ID: I20031113000676 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Tae W Park |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1538133020 PECOS PAC ID: 5799682704 Enrollment ID: I20031223000319 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Donna J Lee |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1467859546 PECOS PAC ID: 1759358898 Enrollment ID: I20040916000749 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Babu Rajendra Prasad Vadlamudi |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1740227735 PECOS PAC ID: 3678534849 Enrollment ID: I20041021000021 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Timothy Lamar Chapman |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1023056199 PECOS PAC ID: 0244294957 Enrollment ID: I20041112000769 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Hyun C Shin |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1336284504 PECOS PAC ID: 9830154251 Enrollment ID: I20041124000890 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Melanie S Hooper |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1033127600 PECOS PAC ID: 9234186362 Enrollment ID: I20050331001162 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Maimoona Hakim Husain |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487731816 PECOS PAC ID: 5496794166 Enrollment ID: I20050502000992 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Katrina Denise Richardson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053399337 PECOS PAC ID: 2961423173 Enrollment ID: I20051215000641 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Hanumaiah Bandla |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1437197167 PECOS PAC ID: 0345252664 Enrollment ID: I20060630000273 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Tabassum Kahkashan |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1134217490 PECOS PAC ID: 5890796049 Enrollment ID: I20070131000039 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Karen L Boyd |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386642791 PECOS PAC ID: 1951303155 Enrollment ID: I20070131000569 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Michele R Haselhuhn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003952045 PECOS PAC ID: 6305948324 Enrollment ID: I20070222000197 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Mareen A Stevens |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1255481479 PECOS PAC ID: 6901900356 Enrollment ID: I20070326000090 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Lynn C Keidan |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1447396254 PECOS PAC ID: 9830293422 Enrollment ID: I20070410000091 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Teri L Baker |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1245364884 PECOS PAC ID: 4688761307 Enrollment ID: I20071029000078 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Edward A Lamsen |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1245257120 PECOS PAC ID: 5294815437 Enrollment ID: I20071231000231 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Alfred C Spitzer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1396766945 PECOS PAC ID: 2062595366 Enrollment ID: I20080211000082 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Puthenparampil G Vijayakumaran |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1669480224 PECOS PAC ID: 3577646421 Enrollment ID: I20080215000069 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jorge S Zuniga |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1689638140 PECOS PAC ID: 1254415052 Enrollment ID: I20080303000322 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Bernice Diop |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1114037082 PECOS PAC ID: 6901981679 Enrollment ID: I20080306000139 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Kai Anderson |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1790901429 PECOS PAC ID: 5496834871 Enrollment ID: I20080509000585 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Debra L Beckman |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609063510 PECOS PAC ID: 6901971837 Enrollment ID: I20080812000545 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Hanif Khan |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1609030147 PECOS PAC ID: 2466529474 Enrollment ID: I20080917000205 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Gianina Cristiu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720232689 PECOS PAC ID: 4082752050 Enrollment ID: I20091111000545 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Daniel J Petersen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1740458538 PECOS PAC ID: 1759412984 Enrollment ID: I20100701000389 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Gerald Tyler |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1780993931 PECOS PAC ID: 3779766803 Enrollment ID: I20110325000711 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Brenda R Scoggins |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1790879021 PECOS PAC ID: 0749468916 Enrollment ID: I20110617000516 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Alisa Diana Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740421767 PECOS PAC ID: 1759559065 Enrollment ID: I20110712000398 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Philip Gilly |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1609849868 PECOS PAC ID: 3274523733 Enrollment ID: I20110803000936 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Leonard F Field |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1922119296 PECOS PAC ID: 9234300369 Enrollment ID: I20110922000128 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Julie Encelewski |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1457647059 PECOS PAC ID: 6103079165 Enrollment ID: I20121227000230 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Michelle D Sessom |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1134468960 PECOS PAC ID: 2860638590 Enrollment ID: I20130424000807 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Ellen O Robey |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1144346354 PECOS PAC ID: 2860635604 Enrollment ID: I20130827000573 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Pamela E Stolz |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1083744460 PECOS PAC ID: 9436392032 Enrollment ID: I20130829000745 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Cheryl A Green |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1831236660 PECOS PAC ID: 5890921076 Enrollment ID: I20131118000445 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Matina Fabian |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1700162153 PECOS PAC ID: 7012149180 Enrollment ID: I20140404000602 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Chelsey E Seiler |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1841562998 PECOS PAC ID: 2567694938 Enrollment ID: I20140417000915 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Angell M Love-jackson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1164832200 PECOS PAC ID: 6204059926 Enrollment ID: I20140528001154 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Charleitte Phillips |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972843126 PECOS PAC ID: 4284850025 Enrollment ID: I20140730002714 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Vernon K Johnson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609164755 PECOS PAC ID: 7315168309 Enrollment ID: I20141015002319 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Laura S Smith |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1114325826 PECOS PAC ID: 8224353420 Enrollment ID: I20150211000173 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Alexander Thomas Parker |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1366658361 PECOS PAC ID: 3274780093 Enrollment ID: I20150323002195 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jennifer L Lewis |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1215052444 PECOS PAC ID: 4688985047 Enrollment ID: I20150625002147 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Prerana N Rajhans |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1083815781 PECOS PAC ID: 6507178761 Enrollment ID: I20150701001470 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Inga Monae Leverett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336526292 PECOS PAC ID: 2365743127 Enrollment ID: I20151221000895 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Leniya Leonard |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1740596758 PECOS PAC ID: 0446553903 Enrollment ID: I20160118000799 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Sarah A Moellenberg |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1073894465 PECOS PAC ID: 5092012799 Enrollment ID: I20160323002123 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Chamara A Mercer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508221409 PECOS PAC ID: 8224335708 Enrollment ID: I20160329000304 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Kevin W Rose |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1245369057 PECOS PAC ID: 1850680604 Enrollment ID: I20160517002420 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Pasha M Streeter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922322684 PECOS PAC ID: 4385874015 Enrollment ID: I20160615000985 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Mary A Bernier |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1720357791 PECOS PAC ID: 4183919038 Enrollment ID: I20160817001328 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Kimberly R Mahaffa |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508284951 PECOS PAC ID: 3173802451 Enrollment ID: I20161108002441 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Poonam R Sripada |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1174889539 PECOS PAC ID: 6103106976 Enrollment ID: I20161213002317 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jenay Lisbon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265980023 PECOS PAC ID: 7012299647 Enrollment ID: I20170116000703 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Andreana S Major |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1871972364 PECOS PAC ID: 8224307533 Enrollment ID: I20170629002410 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Anna K Vantoai |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1477931723 PECOS PAC ID: 2860765997 Enrollment ID: I20170912000364 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Michael Mogan |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1932651015 PECOS PAC ID: 4385919265 Enrollment ID: I20171003004601 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Soha Alammoury |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750730834 PECOS PAC ID: 1557655859 Enrollment ID: I20180205001278 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Honorine N Njita |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124322672 PECOS PAC ID: 6800159294 Enrollment ID: I20180418000050 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Carol Ann Steward |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1396239471 PECOS PAC ID: 6002162385 Enrollment ID: I20180628001101 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Angela Lucas |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1760844922 PECOS PAC ID: 8022364736 Enrollment ID: I20180711002119 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Tracey Helms |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1083162598 PECOS PAC ID: 1557606787 Enrollment ID: I20181217002112 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Ingrid L Blair |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427313121 PECOS PAC ID: 0042555286 Enrollment ID: I20181217002324 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Kimberly R Varga |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508316100 PECOS PAC ID: 1456690700 Enrollment ID: I20190304001052 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Karen Ann Resseguie |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356791479 PECOS PAC ID: 2668712092 Enrollment ID: I20190322000228 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jemica Monique Carter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114492832 PECOS PAC ID: 9234472622 Enrollment ID: I20190529000808 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Dale Switzer |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1861855587 PECOS PAC ID: 5698008282 Enrollment ID: I20190613002035 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Therese A Muir |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1275927980 PECOS PAC ID: 5193068211 Enrollment ID: I20190717002079 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Stacy Goodpaster |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1619016672 PECOS PAC ID: 8022343789 Enrollment ID: I20190717002386 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Neda Habeeb |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1831548536 PECOS PAC ID: 2567753585 Enrollment ID: I20190826000260 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Renita Jon Elder-robinson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508323882 PECOS PAC ID: 8224368865 Enrollment ID: I20190925001772 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Maninderpal Singh Dhillon |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1306226238 PECOS PAC ID: 7315379401 Enrollment ID: I20191111002161 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Tena Payton-vance |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700371085 PECOS PAC ID: 4880016039 Enrollment ID: I20200617001848 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Cayla Marie Yuhn |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1194283200 PECOS PAC ID: 8022430172 Enrollment ID: I20200619000228 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Andrea Denise Motley |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1902240757 PECOS PAC ID: 7315362985 Enrollment ID: I20200730001745 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Barbara Richey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114256377 PECOS PAC ID: 9335399294 Enrollment ID: I20201001002525 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jaleesa Atkins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093332546 PECOS PAC ID: 1052730306 Enrollment ID: I20201006001463 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Dalia F Mammo |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1962908681 PECOS PAC ID: 1153686225 Enrollment ID: I20201028001412 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Crystal A Dussia |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1649896358 PECOS PAC ID: 9133532625 Enrollment ID: I20201229003002 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Daphnee Pierre Louis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043612997 PECOS PAC ID: 5597069955 Enrollment ID: I20210201000287 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Mahdy A Nassar |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1659877090 PECOS PAC ID: 9234494030 Enrollment ID: I20210210003339 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Zaid Baha |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1447604608 PECOS PAC ID: 0749680569 Enrollment ID: I20210616002113 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jessica Billups |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1356810030 PECOS PAC ID: 0941604078 Enrollment ID: I20210811001118 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Katherine Kelley |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1336704592 PECOS PAC ID: 6709278344 Enrollment ID: I20220112000189 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Vindhya R Baddigam |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1811493430 PECOS PAC ID: 8527313360 Enrollment ID: I20220125000871 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Natasha Zlateski |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831845460 PECOS PAC ID: 7911393079 Enrollment ID: I20220330000718 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Samuel Malian |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1265095681 PECOS PAC ID: 2961735386 Enrollment ID: I20220420001213 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Sherry Smith |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1063756971 PECOS PAC ID: 0648667618 Enrollment ID: I20220420003151 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jenneatta Mitchell |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1811445687 PECOS PAC ID: 6901283977 Enrollment ID: I20220512000571 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Emmanuel M Metayer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609315886 PECOS PAC ID: 4183994452 Enrollment ID: I20220621000115 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Danielle Schilhaneck |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1497224596 PECOS PAC ID: 1759762529 Enrollment ID: I20220726000622 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Stephanie Anne Swisher |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1841321726 PECOS PAC ID: 5698158582 Enrollment ID: I20220809004013 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jon Williams |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1841654969 PECOS PAC ID: 3274900667 Enrollment ID: I20221027000937 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Saara Anjum Mohammed |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1396366944 PECOS PAC ID: 2769803899 Enrollment ID: I20230327001445 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Katie Beth Toye |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1730845637 PECOS PAC ID: 9436519931 Enrollment ID: I20230715000359 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Danielle M Mcbride |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1548753585 PECOS PAC ID: 0446606768 Enrollment ID: I20231023003403 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Anthony James Dondero |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1932710209 PECOS PAC ID: 6204288319 Enrollment ID: I20240113000555 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Jessica Nichole Beane |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1326418021 PECOS PAC ID: 8325499643 Enrollment ID: I20240116003054 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Alana Celia Davis |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1790022028 PECOS PAC ID: 9537511324 Enrollment ID: I20240117002365 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Christal Marie Krause |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1669894044 PECOS PAC ID: 7618329343 Enrollment ID: I20240118002613 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Theresa J Nolden |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1427589449 PECOS PAC ID: 5294187837 Enrollment ID: I20240118003205 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Steven James Helsel |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1447502596 PECOS PAC ID: 6103279286 Enrollment ID: I20240124004283 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Dawn Michelle Hamilton |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1841327566 PECOS PAC ID: 8224481171 Enrollment ID: I20240127000454 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Nadia Emilia Coroiu |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1235527334 PECOS PAC ID: 8325483415 Enrollment ID: I20240228003082 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Alex C Lindsay |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1396315453 PECOS PAC ID: 6709221831 Enrollment ID: I20240228004592 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
| Provider Name | Deshara Monique Mckinney |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609352780 PECOS PAC ID: 0244675957 Enrollment ID: I20240304001137 |
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
News Archive
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.
Only about two out of every 100 babies (1.8 percent) were screened at birth for congenital heart defects (CHDs) because the hospital or birthing center where the baby was born routinely screens all newborns for CHDs - the number-one birth defect and leading killer of infants and newborns. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.
A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.
› Verified 8 days ago
Oakwood Healthcare Center - Westland Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2001 S Merriman Rd, Suite 100, Westland, MI 48186 Phone: 734-727-1000 | |
Beginning Step Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32715 Dorsey St, Westland, MI 48186 Phone: 734-641-1141 Fax: 734-641-1142 | |
New Aspirations Counseling & Consulting Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 33250 Warren Rd Ste 14, Westland, MI 48185 Phone: 734-224-2797 | |
Freedom First Enterprises, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 33250 Warren Rd Ste 14, Westland, MI 48185 Phone: 313-670-5726 | |
Primacare, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 28303 Joy Rd, Westland, MI 48185 Phone: 734-513-1122 Fax: 734-421-1405 | |
Goodwill Industries Of Greater Detroit Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 28526 Van Born Rd, Westland, MI 48186 Phone: 734-467-6600 Fax: 734-467-6633 | |
Daylight Counseling, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 33300 Warren Rd, Suite 17, Westland, MI 48185 Phone: 734-331-0773 |